Background: Data on surgical management of breast liver metastasis are limited. We sought to determine the safety and long-term outcome of patients undergoing hepatic resection of breast cancer
Introduction
Breast cancer is the most frequently diagnosed cancer in the Western world and in the United States more than 40,000 patients are estimated to have died from breast cancer in 2014 alone. [1] [2] [3] [4] Approximately 30% of patients with breast cancer will develop distant metastases at some point during their disease course. 5 While liver is the third most frequent site of metastatic spread, only 5-25% of patients will have isolated breast cancer liver metastases (BCLM) and will, in turn, be eligible for liverdirected surgery. 6 For these patients, a recent meta-analysis reported a 5-year survival of 39% following curative intent liver resection of BCLM. 7 Furthermore, median perioperative morbidity and mortality after liver resection of BCLM was reported to be 13% and 0.3%, respectively. 7 While the FDA has approved over 25 oncology drugs to treat breast cancer, there are disparate response rates with systemic chemotherapy. 8 Specifically, while up to 90% of primary tumors may respond to chemotherapy, systemic therapy is less effective for metastatic lesions, as only about 50% of metastatic lesions will respond. 8 The lower response rate for metastatic breast cancer may be due to a higher likelihood of acquired therapeutic resistance during the course of treatment. 9, 10 In addition, among those patients with metastatic breast tumors that lose estrogen and progesterone receptor positivity, the effectiveness of hormonal treatments is even more limited.
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Given that BCLM is a systemic disease, surgeons have historically been less enthusiastic about operating on these patients. 12 As a result, most data on surgical management of BCLM have come from small, retrospective studies. 7, 13, 14 In fact, only a handful of single-institution studies had sufficient sample size to report on clinicopathologic prognostic factors in multivariable analysis. 7, [15] [16] [17] [18] As such, data on selection of patients with BCLM who might potentially benefit from a liver resection are lacking. The aim of the current study was to define the long-term outcomes of a select group of patients who underwent resection of BCLM, as well as identify which factors were associated with prognosis using a large international, multicenter collaborative database. For each patient, sociodemographic data were collected including age, gender, race. Clinicopathological data on the primary tumor including TNM stage, presence of nodal disease, final resection margin, focality, localization, hormone receptor status, and type of surgery, as well as information on the BCLM, presence of extrahepatic metastases and receipt of adjuvant therapy were collected. Using the final pathology report, the presence of disease at the resection margin (R0: no disease at resected margin, R1: presence of disease at the resected surgical margin, R2: presence of macroscopic disease at the resection margin) and the presence of lymph node metastases were determined. Surgery specific information was also collected including the extent of surgery (minor, <3 Couinaud segments vs. major, 3 Couinaud segments) was determined, as well as the receipt of hormonal/systemic therapy. Complications with a Clavien-Dindo grade 3 were considered major complications.
Methods

Data sources and patient population
Statistical analysis
Categorical variables were described as whole numbers and percentages, while continuous variables were reported as medians with interquartile (IQR) range. The primary outcome of the study was OS, which was defined as the time from the date of surgery to the date of death or date of last available follow-up, as appropriate. OS was estimated using the Kaplan-Meier method and compared between patient groups using the log-rank test. Cox proportional hazards regression analysis was utilized to identify potential risk factors associated with a worse OS. Specifically, associations between OS and margin status after BCLM surgery, as well as BCLM size were evaluated. Results from the Cox proportional hazards regression analysis were reported as hazard ratios (HR) with corresponding 95% confidence intervals (95% CI). Factors with a p < 0.10 were included into the multivariable analysis. All analyses were performed using SPSS 22.0 (IBM, New York). All tests were two-tailed and a p < 0.05 was used to define statistical significance.
Results
Demographic and clinicopathologic characteristics
A total of 131 patients underwent a resection for BCLM and met inclusion criteria (Table 1) . Median patient age was 54.9 years (IQR 46-66); all patients were female. Over ninety percent of patients were Caucasian (n = 121, 92.4%); 10 were AfricanAmerican (7.6%). Most primary tumors were unifocal (n = 92, 89.3%) with primary tumors being roughly equally distributed in the right (n = 54, 48.6%) and left (n = 53, 47.7%) breasts; 4 (3.6%) patients had bilateral primary tumors. Surgery for the primary breast tumor largely consisted either of a partial mastectomy (n = 53, 46.5%) or a modified radical mastectomy (n = 42, 36.8%). On final pathology, the majority of primary breast tumors were classified as either T1 or T2 (n = 81, 89.0%); however, a small number of patients (n = 10, 11%) had an advanced T3 or T4 primary breast cancer. Most patients (n = 58, 59.8%) had associated lymph node metastases; in contrast, only 5 (5.1%) patients had a positive surgical margin. Regarding hormonal receptor status, 79 (76.7%) patients had an estrogen positive tumor, while 74 (74%) women had a progesterone positive tumor; 54 (54.5%) patients had a HER2/neu positive tumor and 9 patients had a Ki-67 > 14%. After diagnosis of BCLM, 39 patients received chemotherapy, 51 patients received hormonal therapy and 35 received biological therapy. 55 (69.6%) patients who received neoadjuvant therapy had a measurable response.
Data pertaining to BCLM are included in Table 2 . BLCM were diagnosed at a median of 34.0 months from the time of surgery for the primary breast tumor. The median time that elapsed between diagnosis and surgical treatment of BCLM was 2.2 months (IQR 0-12.7). At the time of surgery for BCLM, roughly one-third of resections (n = 43, 37.1%) involved 3 Couinaud segments. On final histopathology, a negative microscopic margin (R0) was obtained in 90.8% (n = 108) of patients; 8.4% (n = 10) of patients had a microscopically positive margin (R1). Median tumor size was 3.0 cm (IQR, 2.0-5.0). At the time of BCLM resection, 66 (73.3%) patients had a tumor with positive estrogen receptor status, while 53 (59.6%) patients had a tumor with positive progesterone receptor status. Regarding extrahepatic disease, 16 patients (13.3%) had distant metastases at the time of surgery.
There were no procedure-related deaths within 90-days, however almost one quarter (n = 29, 22.8%) of patients experienced a complication. Among patients who had a complication 12 (41.3%) had a minor complication, while 17 (58.6%) had a major complication. Postoperatively 41 (51.9%) patients received cytotoxic systemic chemotherapy while 43 (47.8%) women received hormonal therapy. Table 1 ). Specifically, the median survival of patients with tumors <3.0 cm was 58.8 months versus 53.3 months for patients with tumors 3.0 cm (p = 0.041) (Fig. 1) . Similarly, patients who underwent an R0 resection had a median survival of 58.8 months, whereas median survival among patients who had an R1 resection was only 28.2 months (p < 0.001) (Fig. 2) . Of note, extrahepatic disease and estrogen/ progesterone receptor status were not associated with long-term survival (both p > 0.05). On multivariable analysis, after adjusting for other clinicopathologic factors, BCLM tumor size (HR 1.03, 95% CI 1.01-1.06; p = 0.002) and positive surgical margin status (HR 3.57, 95% CI 1.40-9.16; p = 0.008) remained associated with OS among patients with BCLM.
Discussion
Because metastatic breast cancer is largely a systemic disease, surgery has traditionally had a limited role in the treatment of these patients. While many centers employ hepatic resection for well-selected BCLM patients, empiric data to support surgical management is still lacking as most data come from small, single center studies. 12 In turn, in clinical practice cytotoxic chemotherapy and hormonal manipulation have been preferred to treat patients with BCLM. There has been a growing interest, however, in employing surgical approaches for patients with nonneuroendocrine, non-colorectal liver metastasis. 12 In fact,
Adam and colleagues have noted that the dogma that surgical therapy has no role in the treatment of cancer patients with systemic disease might no longer be valid. 16 To this end, over the last several decades there has been increased reports of liver resection for BCLM. Specifically, while only one study on liver resection for BCLM was published prior to 1990, four reports were published between 1990 and 2000, and 23 have been published since 2000. 19 Most of these studies, however, were small, single center studies and the use of resection for BCLM remains controversial. As a result, there is an ongoing debate about the benefit of surgical resection. The current study is important because, using one of the largest, multi-institutional cohorts to date, we demonstrated that well-selected patients with BCLM can have a relatively long-term survival after surgical resection. Specifically, following resection of BCLM, median and 3-year OS were 53.4 months and 75.2%, respectively. Of note, most patients were diagnosed during regular follow up (87.6%) with a relatively long disease-free period (median, 34.0 months). In addition, those patients with small tumors and who had an R0 resection benefited the most (Figs 1 and 2 ). As such, our recommendation is that surgery of BCLM should largely be reserved for women with metachronous disease who have had a long-disease free-period in which the metastatic disease burden is low (i.e. small tumors) and in which all disease can be resected with a negative surgical margin. Prior to the current study, Adam et al. had reported the largest study to date (n = 85) of patients undergoing liver resection for BCLM. 16 In that study, the authors reported a median survival of 38 months with a 5-year OS of 37% following resection of BCLM. 16 In a separate more recent study, Sadot et al. reported a Figure 1 Overall survival stratified by diameter of the largest breast cancer liver metastases median survival of 50 months and a 5-year OS of 38% for patients with BCLM who had undergone liver resection. 20 Interestingly, some authors have reported a 5-year OS even as high as 61%. 21 Of note, these surprisingly high survival rates might be the result of very careful patient selection. As such, they might not reflect the survival noted in overall clinical practice. In the current study, using a multi-center database, 3-year OS following liver resection for BCLM was 75.2%. Selection of patients for surgery should, however, be discriminating in order to achieve these results. For example, previous data on surgery for BCLM have largely included patients with small, solitary lesions. 7 In one study that compared a medically treated group of patients versus a matched surgically treated cohort, patients had a median number of one liver metastasis (IQR, 1-2) and a median tumor size of 3 cm (IQR, 2-5). 20 Similarly, in the current study, the majority of patients had only one liver metastasis that was relatively small in size. In fact, metastatic tumor size was associated with long-term outcomes (HR 1.03, 95% CI 1.01-1.06; p = 0.002). These data were consistent with a previous report by Groeschl and colleagues who similarly noted that BCLM tumor size was an independent predictor of worse survival.
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A recent study from Memorial Sloan Kettering Cancer Center questioned the benefit associated with surgical treatment of BCLM. 20 In this study, the authors reported a similar survival when matched cohorts of surgically and medically treated patients were compared. 20 Among 69 patients who underwent surgery/ablation for BCLM, the median recurrence-free interval was 28.5 months and there was no significant difference in OS between the surgical and medical cohorts. In turn, the authors concluded that, while hepatic resection and/or ablation was not associated with a survival advantage, significant recurrence-free intervals could be accomplished with surgical treatment. In a separate study by Spolverato et al. the authors estimated the costeffectiveness of liver resection followed by adjuvant systemic therapy relative to systemic therapy alone for patients with BCLM using a decision-analytic Markov model. 1 Interestingly, the net health benefit of hepatic resection was 10.9 quality adjusted life months (QALMS) with letrozole as systemic therapy and only 0.3 QALMs when docetaxel + trastuzumab were used as systemic therapy. Furthermore, the addition of newer biological agents significantly decreased the cost-effectiveness of conventional systemic therapy alone relative to hepatic resection. As such, liver resection in patients with BCLM was determined to be cost-effective when compared to systemic therapy alone, particularly in ER + tumors or when modern agents were used. Collectively, the data would therefore strongly suggest that surgical intervention should be considered in highly selected patients with the goal of providing time off of systemic chemotherapy. 1, 20 The current study had several limitations that should be considered when interpreting the results. Given its retrospective nature, selection bias in how patients were chosen for surgical therapy was likely. The non-random selection of patients for liver resection of BCLM versus systemic treatment should not, however, have affected our underlying hypothesis, which was focused on determining the long-term outcomes of surgery in a select subset of patients with BCLM. However, the "true" benefit of surgery could not be estimated, as an appropriate control group of patients who received modern systemic chemotherapy alone was not available. Due to the rarity of resection of BCLM, the study also spanned a long period of time during which adjuvant treatments undoubtedly varied. Finally, although the study combined data from eight major hepatobiliary centers and is the largest cohort of surgically resected BCLM reported to date, the overall sample size was still relatively small. As such, some statistical analyses were limited and causal inferences should be considered in light of this limitation.
In conclusion, patients with small tumors that were resected with a negative surgical margin had reasonable long-term outcomes following surgical intervention. As such, in conjunction with increasingly efficacious chemotherapy for BCLM, surgical resection of BCLM may be appropriate as part of a multimodality, multi-disciplinary approach to patients who suffer from this disease.
